methacetin has been researched along with Liver Diseases in 17 studies
methacetin: RN given refers to parent cpd
methacetin : A member of the class of acetamides that is paracetamol in which the hydrogen of phenolic hydroxy group has been replaced by a methyl group.
Liver Diseases: Pathological processes of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The mechanism of 13C-methacetin breath test is set forth clearly with the analysis of pharmacokinetics mode, and the measuring method of 13C-methacetin breath test and its clinical applications in the diagnosis of liver diseases are reported in detail." | 7.69 | 13C-methacetin breath test parameter S for liver diseases diagnosis. ( Liu, C; Shen, Q; Wang, X; Wen, Q; Xu, S; Yang, Z; Zeng, W; Zhang, W; Zhu, D, 1996) |
| "The mechanism of 13C-methacetin breath test is set forth clearly with the analysis of pharmacokinetics mode, and the measuring method of 13C-methacetin breath test and its clinical applications in the diagnosis of liver diseases are reported in detail." | 3.69 | 13C-methacetin breath test parameter S for liver diseases diagnosis. ( Liu, C; Shen, Q; Wang, X; Wen, Q; Xu, S; Yang, Z; Zeng, W; Zhang, W; Zhu, D, 1996) |
| "As liver diseases are a major health problem and especially the incidence of metabolic liver diseases like non-alcoholic fatty liver disease (NAFLD) is rising, the demand for non-invasive tests is growing to replace liver biopsy." | 2.50 | Critical appraisal of 13C breath tests for microsomal liver function: aminopyrine revisited. ( Bast, A; de Vries, H; Koek, GH; Nikkessen, S; Pijls, KE; Wodzig, WK, 2014) |
| "Allopurinol and caffeine have been used to measure metabolite formation followed by renal elimination of both parent substance and metabolite." | 1.28 | Liver function assessment by drug metabolism. ( Barstow, L; Small, RE, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (17.65) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 3 (17.65) | 29.6817 |
| 2010's | 6 (35.29) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Holzhütter, HG | 1 |
| Wuensch, T | 1 |
| Gajowski, R | 1 |
| Berndt, N | 1 |
| Bulik, S | 1 |
| Meierhofer, D | 1 |
| Stockmann, M | 3 |
| Haimerl, M | 1 |
| Fuhrmann, I | 1 |
| Poelsterl, S | 1 |
| Fellner, C | 1 |
| Nickel, MD | 1 |
| Weigand, K | 1 |
| Dahlke, MH | 1 |
| Verloh, N | 1 |
| Stroszczynski, C | 1 |
| Wiggermann, P | 1 |
| Górowska-Kowolik, K | 1 |
| Chobot, A | 1 |
| Kwiecień, J | 1 |
| Theilig, D | 1 |
| Tsereteli, A | 1 |
| Elkilany, A | 1 |
| Raabe, P | 1 |
| Lüdemann, L | 1 |
| Malinowski, M | 2 |
| Pratschke, J | 1 |
| Hamm, B | 1 |
| Denecke, T | 1 |
| Geisel, D | 1 |
| Pijls, KE | 1 |
| de Vries, H | 1 |
| Nikkessen, S | 1 |
| Bast, A | 1 |
| Wodzig, WK | 1 |
| Koek, GH | 1 |
| Jara, M | 1 |
| Bednarsch, J | 1 |
| Lock, JF | 1 |
| Schulz, A | 1 |
| Seehofer, D | 1 |
| Stravitz, RT | 1 |
| Ilan, Y | 3 |
| Lalazar, G | 1 |
| Adar, T | 1 |
| Kasicka-Jonderko, A | 1 |
| Loska, D | 1 |
| Jonderko, K | 1 |
| Kaminska, M | 1 |
| Błonska-Fajfrowska, B | 1 |
| Richter, T | 1 |
| Krumbiegel, P | 1 |
| Beyreiss, K | 1 |
| Zeng, W | 1 |
| Zhang, W | 1 |
| Xu, S | 1 |
| Yang, Z | 1 |
| Liu, C | 1 |
| Zhu, D | 1 |
| Wen, Q | 1 |
| Shen, Q | 1 |
| Wang, X | 1 |
| Lara Baruque, S | 1 |
| Razquin, M | 1 |
| Jimenez, I | 1 |
| Vazquez, A | 1 |
| Gisbert, JP | 1 |
| Pajares, JM | 1 |
| Barstow, L | 1 |
| Small, RE | 1 |
| Matsumoto, K | 1 |
| Suehiro, M | 1 |
| Iio, M | 1 |
| Kawabe, T | 1 |
| Shiratori, Y | 1 |
| Okano, K | 1 |
| Sugimoto, T | 1 |
| Qiu, YY | 1 |
| Tang, ZD | 2 |
| Xia, ZQ | 1 |
| Dai, TC | 1 |
| Hu, YE | 1 |
| Li, J | 1 |
| Lu, YJ | 1 |
| Zhang, NL | 1 |
| Qiu, YQ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| 13C-Methacetin Breath Test for the Prediction of Outcome in in Acute Liver Injury or Acute Liver Failure[NCT02786836] | Phase 2/Phase 3 | 76 participants (Actual) | Interventional | 2016-06-10 | Completed | ||
| Development of a Breath Test for Monitoring Liver Metabolic Function in Patients With Chronic Liver Disease and Cirrhosis[NCT00244569] | Phase 3 | 120 participants (Anticipated) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The relationship between the cPDR (cumulative PDR of metabolized 13C-Methacetin 20 minutes after ingestion) in single time points of MBT measurements and TFS and non-TFS (death/transplant) at Day 21. (NCT02786836)
Timeframe: The first MBT reading either on Day 1 or Day 2 and Day 21
| Intervention | percentage per hour (Mean) | |
|---|---|---|
| Day 1 or 2 MBT/transplant free survival at Day 21 | Day 1 or 2 MBT & Day 21 non-TFS | |
| 13C-Methacetin Breath Test (MBT) | 1.4 | 0.2 |
Peak PDR is the maximal percent dose recovery (PDR) rate which reflects the maximum rate of metabolism of 13C-methacetin measured as the change in 13CO2 / 12CO2 (normal carbon dioxide) ratio after ingestion of 13C-methacetin normalized using the patient's height and weight. The distributions of mean PDR Peak values were compared between TFS (transplant free survival) and non-TFS (death/transplant) at Day 21. (NCT02786836)
Timeframe: Days 1 and 21
| Intervention | percentage per hour (Mean) | |
|---|---|---|
| Mean Peak PDR for TFS subjects at Day 21 | Mean Peak PDR for non-TFS subjects at Day 21 | |
| 13C-Methacetin Breath Test (MBT) | 10.2 | 1.9 |
This outcome is similar to the peak PDR defined in the primary outcome but as a secondary we are looking at Day 1 or Day 2 peak PDR values. Peak PDR is the maximal percent dose recovery (PDR) rate which reflects the maximum rate of metabolism of 13C-methacetin measured as the change in 13CO2 / 12CO2 ratio after ingestion of 13C-methacetin normalized using the patient's height and weight. The distributions of mean PDR Peak values were compared between TFS and non-TFS (death/transplant) at Day 21. (NCT02786836)
Timeframe: The first MBT reading either on Day 1 or Day 2 and Day 21
| Intervention | percentage per hour (Mean) | |
|---|---|---|
| Day 1 or 2 MBT & Day 21 TFS | Day 1 or 2 MBT & Day 21 non-TFS | |
| 13C-Methacetin Breath Test (MBT) | 9.1 | 2.3 |
4 reviews available for methacetin and Liver Diseases
| Article | Year |
|---|---|
Critical appraisal of 13C breath tests for microsomal liver function: aminopyrine revisited.
Topics: Acetamides; Aminopyrine; Aryl Hydrocarbon Hydroxylases; Breath Tests; Caffeine; Carbon Isotopes; Cyt | 2014 |
[Enhancing safety in liver surgery using a new diagnostic tool for evaluation of actual liver function capacity - The LiMAx test].
Topics: Acetamides; Breath Tests; Cause of Death; Hepatectomy; Humans; Liver Diseases; Liver Failure; Liver | 2014 |
Potential use of metabolic breath tests to assess liver disease and prognosis: has the time arrived for routine use in the clinic?
Topics: Acetamides; Biomarkers; Breath Tests; Disease Progression; Fibrosis; Humans; Liver; Liver Diseases; | 2017 |
Review article: the assessment of liver function using breath tests.
Topics: Acetamides; Breath Tests; Female; Humans; Liver Diseases; Liver Function Tests; Male; Treatment Outc | 2007 |
1 trial available for methacetin and Liver Diseases
| Article | Year |
|---|---|
Point-of-care continuous (13)C-methacetin breath test improves decision making in acute liver disease: results of a pilot clinical trial.
Topics: Acetamides; Acute Disease; Adolescent; Adult; Breath Tests; Carbon Isotopes; Female; Hepatitis; Hepa | 2009 |
12 other studies available for methacetin and Liver Diseases
| Article | Year |
|---|---|
A novel variant of the
Topics: Acetamides; Acetaminophen; Administration, Oral; Adult; Age Factors; Breath Tests; Carbon Dioxide; C | 2020 |
Gd-EOB-DTPA-enhanced T1 relaxometry for assessment of liver function determined by real-time
Topics: Acetamides; Aged; Breath Tests; Carbon Isotopes; Contrast Media; Disease Progression; Female; Gadoli | 2018 |
Breath test using
Topics: Acetamides; Adolescent; Anorexia Nervosa; Body Height; Body Mass Index; Body Weight; Breath Tests; C | 2018 |
Gd-EOB-DTPA-enhanced MRI T1 relaxometry as an imaging-based liver function test compared with
Topics: Acetamides; Breath Tests; Carbon Isotopes; Contrast Media; Female; Gadolinium DTPA; Humans; Image En | 2020 |
Interference of acute cigarette smoking with [¹³C]methacetin breath test.
Topics: Acetamides; Adult; Breath Tests; Carbon Dioxide; Carbon Isotopes; Female; Humans; Liver; Liver Disea | 2011 |
[15N liver function test in underweight infants, hypotrophic at birth].
Topics: Acetamides; Child, Preschool; Female; Fetal Growth Retardation; Follow-Up Studies; Humans; Infant; I | 1993 |
13C-methacetin breath test parameter S for liver diseases diagnosis.
Topics: Acetamides; Breath Tests; Carbon Dioxide; Carbon Isotopes; Humans; Liver Diseases; Mathematics; Oxid | 1996 |
13C-phenylalanine and 13C-methacetin breath test to evaluate functional capacity of hepatocyte in chronic liver disease.
Topics: Acetamides; Adult; Breath Tests; Carbon Isotopes; Chronic Disease; Female; Hepatocytes; Humans; Live | 2000 |
Liver function assessment by drug metabolism.
Topics: Acetamides; Adult; Allopurinol; Aminopyrine; Caffeine; Half-Life; Humans; Indocyanine Green; Lidocai | 1990 |
[13C]methacetin breath test for evaluation of liver damage.
Topics: Acetamides; Adult; Breath Tests; Carbon Dioxide; Carcinoma, Hepatocellular; Female; Humans; Liver Ci | 1987 |
Diagnostic value of C-13-methacetin breath test in liver diseases.
Topics: Acetamides; Breath Tests; Carbon Isotopes; Hepatic Encephalopathy; Hepatitis; Humans; Liver Cirrhosi | 1988 |
[Assessment of liver function with the 13C methacetin breath test].
Topics: Acetamides; Adolescent; Adult; Breath Tests; Carbon Isotopes; Female; Hepatitis, Chronic; Humans; Li | 1986 |